Literature DB >> 14657954

Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma.

Karine Llinares1, Fabienne Escande, Sébastien Aubert, Marie-Pierre Buisine, Carme de Bolos, Surinder K Batra, Bernard Gosselin, Jean-Pierre Aubert, Nicole Porchet, Marie-Christine Copin.   

Abstract

The distinction between pleural malignant mesothelioma and pleural infiltration by adenocarcinomas has complex therapeutic and medicolegal implications. Although the panel of adenocarcinoma-associated antibodies and one or two mesothelioma markers is useful in this purpose, most of these antibodies are not totally specific. We determined the diagnostic value of MUC4 immunostaining in this issue. MUC4 gene expression was also studied by in situ hybridization and RT-PCR. MUC4 is a membrane-bound mucin that has been suggested to be implicated in malignant progression in humans and rats. The MUC4 gene is expressed in various normal epithelial tissues of endodermic origin and carcinomas. In the respiratory tract, MUC4 transcripts have been detected in normal respiratory epithelium and lung carcinomas. MUC4 protein was expressed in 32 of 35 (91.4%) lung adenocarcinomas on paraffin-embedded tissue. None of the 41 malignant mesotheliomas nor the 32 cases of benign mesothelial cells expressed MUC4 at the protein and mRNA levels. We conclude that MUC4 is a very specific (100%) and sensitive (91.4%) marker of lung adenocarcinomas on paraffin-embedded tissue that could be useful in diagnostic practice in the distinction between malignant mesothelioma and adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14657954     DOI: 10.1038/modpathol.3800027

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.

Authors:  Dong-Hoe Koo; Hee Jin Lee; Jin-Hee Ahn; Dok Hyun Yoon; Sung-Bae Kim; Gyungyub Gong; Byung Ho Son; Sei Hyun Ahn; Kyung Hae Jung
Journal:  Tumour Biol       Date:  2015-03-01

Review 3.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

4.  Prognostic value of mucin 4 expression in colorectal adenocarcinomas.

Authors:  Chandrakumar Shanmugam; Nirag C Jhala; Venkat R Katkoori; Wen Wan; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  Cancer       Date:  2010-08-01       Impact factor: 6.860

5.  The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection.

Authors:  David Buob; Harold Fauvel; Marie-Pierre Buisine; Stéphanie Truant; Christophe Mariette; Nicole Porchet; Agnès Wacrenier; Marie-Christine Copin; Emmanuelle Leteurtre
Journal:  Dig Dis Sci       Date:  2011-12-25       Impact factor: 3.199

6.  Establishment and characterization of novel gastric signet-ring cell and non signet-ring cell poorly differentiated adenocarcinoma cell lines with low and high malignant potential.

Authors:  Hiroki Murakami; Hayao Nakanishi; Harunari Tanaka; Seiji Ito; Kazunari Misawa; Yuuichi Ito; Yuzuru Ikehara; Eisaku Kondo; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2012-03-27       Impact factor: 7.370

7.  MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.

Authors:  Vishwa Jeet Amatya; Kei Kushitani; Amany Sayed Mawas; Yoshihiro Miyata; Morihito Okada; Takumi Kishimoto; Kouki Inai; Yukio Takeshima
Journal:  Mod Pathol       Date:  2017-01-27       Impact factor: 7.842

Review 8.  Muc4/MUC4 functions and regulation in cancer.

Authors:  Kermit L Carraway; George Theodoropoulos; Goldi A Kozloski; Coralie A Carothers Carraway
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 9.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

Review 10.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.